Get the Stockscreener App
0.8839
5.18%
-0.0483
Pre-market:
.92
0.0361
+4.08%
Rani Therapeutics Holdings Inc stock is traded at $0.8839, with a volume of 695.49K.
It is down -5.18% in the last 24 hours and up +5.25% over the past month.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
See More
Previous Close:
$0.9322
Open:
$0.93
24h Volume:
695.49K
Relative Volume:
0.68
Market Cap:
$88.22M
Revenue:
$1.63M
Net Income/Loss:
$-40.95M
P/E Ratio:
-1.506
EPS:
-0.5869
Net Cash Flow:
$-18.80M
1W Performance:
+1.83%
1M Performance:
+5.25%
6M Performance:
-64.64%
1Y Performance:
-18.16%
1-Day Range:
$0.882
$0.9385
1-Week Range:
$0.8302
$0.9626
52-Week Range:
$0.387
$3.87
Rani Therapeutics Holdings Inc Stock (RANI) Company Profile
Name
Rani Therapeutics Holdings Inc
Sector
Industry
Phone
(408) 457-3700
Address
2051 RINGWOOD AVENUE, SAN JOSE
Compare RANI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RANI
Rani Therapeutics Holdings Inc
|
0.8839 | 88.22M | 1.63M | -40.95M | -18.80M | -0.5869 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Rani Therapeutics Holdings Inc Stock (RANI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Initiated | Lake Street | Buy |
| Aug-02-24 | Initiated | Oppenheimer | Outperform |
| Jun-14-24 | Initiated | Maxim Group | Buy |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jul-27-22 | Initiated | H.C. Wainwright | Buy |
| Jun-13-22 | Initiated | Wedbush | Outperform |
View All
Rani Therapeutics Holdings Inc Stock (RANI) Latest News
MSN Money - MSN
RANI Price Today: Rani Therapeutics Holdings, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Rani Therapeutics | SCHEDULE 13G: Others - Moomoo
Vanguard Capital Management takes 5.12% stake in Rani Therapeutics (RANI) - Stock Titan
Rani Therapeutics Holdings (RANI) price target decreased by 12.50% to 7.14 - MSN
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Rani Therapeutics Holdings (RANI) price target decreased by 13.51% to 8.16 - MSN
Form DEF 14AOther definitive proxy statements - ADVFN
Alireza Javadi Net Worth (2026) - GuruFocus
Rani Therapeutics | ARS: Annual Report to Security Holders - Moomoo
Rani Therapeutics (NASDAQ: RANI) sets 2026 virtual meeting on board elections and auditor - Stock Titan
[ARS] Rani Therapeutics Holdings, Inc. SEC Filing - Stock Titan
Rani Therapeutics (NASDAQ:RANI) Earns Buy Rating from Analysts at Lake Street Capital - MarketBeat
Rani Therapeutics appoints Sara Kenkare-Mitra as advisor By Investing.com - Investing.com Nigeria
Rani Therapeutics appoints Sara Kenkare-Mitra as advisor - Investing.com
Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy - The Manila Times
Drug approval veteran joins Rani to shape oral biologics push - Stock Titan
Update Report: Can Rani Therapeutics Holdings Inc reach all time highs this yearPortfolio Update Report & Fast Exit Strategy with Risk Control - baoquankhu1.vn
Is Rani (RANI) Stock a Good Buy in 2026 | Price at $0.82, Up 0.86%Collaborative Trading Signals - Cổng thông tin điện tử Tỉnh Sơn La
Published on: 2026-04-07 19:26:18 - baoquankhu1.vn
Is Rani (RANI) Stock Stronger Than Peers | Price at $0.88, Up 4.41%Elite Alerts - Cổng thông tin điện tử tỉnh Tây Ninh
RANI Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Canaccord Genuity Group Lowers Rani Therapeutics (NASDAQ:RANI) Price Target to $5.00 - MarketBeat
CCORF Maintains Rani Therapeutics(RANI.US) With Buy Rating, Cuts Target Price to $5 - Moomoo
Market Review: Can Rani Therapeutics Holdings Inc reach all time highs this yearSwing Trade & Safe Entry Zone Tips - baoquankhu1.vn
Can Rani Therapeutics Holdings Inc beat the S P 5002026 Weekly Recap & Community Consensus Trade Alerts - baoquankhu1.vn
Loss Report: Is Rani Therapeutics Holdings Inc likely to announce a buybackMarket Risk Summary & High Conviction Buy Zone Picks - baoquankhu1.vn
RANI SEC FilingsRani Therapeutics Holdings, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Equities Analysts Offer Predictions for RANI Q1 Earnings - MarketBeat
Companies Like Rani Therapeutics Holdings (NASDAQ:RANI) Are In A Position To Invest In Growth - Yahoo Finance
Rani Therapeutics | 3: Initial statement of beneficial ownership of securities- Javadi Alireza - Moomoo
Rani Therapeutics (RANI) CTO discloses initial stock, RSU and option holdings - stocktitan.net
Rani Therapeutics | SCHEDULE 13G/A: Others - Moomoo
Vanguard disaggregates holdings; reports 0 RANI shares (RANI) - Stock Titan
Rani Therapeutics (NASDAQ:RANI) Given "Buy" Rating at HC Wainwright - MarketBeat
Rani Therapeutics 2025 Annual Report: Oral Biologics Pipeline, Clinical Updates, and Risk Factors 535657 - Minichart
Earnings Call Summary | Rani Therapeutics(RANI.US) Q4 2025 Earnings Conference - news.futunn.com
Earnings call transcript: Rani Therapeutics Q4 2025 sees improved liquidity but misses EPS forecast - Investing.com Australia
Earnings call transcript: Rani Therapeutics Q4 2025 sees improved liquidity but misses EPS forecast By Investing.com - Investing.com South Africa
Rani Therapeutics Q4 Earnings Call Highlights - MarketBeat
Rani Therapeutics Holdings Inc reports results for the quarter ended September 30Earnings Summary - TradingView
RANI: Major Chugai deal, RT-114 clinical progress, and strengthened finances mark a transformative 2025 - TradingView
RANI: Advanced pipeline, secured major Chugai deal, and extended cash runway into Q4 2027 - TradingView
Rani Therapeutics 2025 10-K: $1.63M revenue, $(0.45) EPS - TradingView
RANI: Net loss improved to $41.0M in 2025, with $49.7M cash and strengthened by a $60.3M private placement - TradingView
Rani Therapeutics (NASDAQ: RANI) boosts cash, advances oral biologics pipeline - Stock Titan
Rani Therapeutics (NASDAQ:RANI) Announces Quarterly Earnings Results - MarketBeat
Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update - The Manila Times
[8-K] Rani Therapeutics Holdings, Inc. Reports Material Event - Stock Titan
Rani Therapeutics Holdings Inc Stock (RANI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):